The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated.

* This study is seeking participants who: Are aged 12 years or older.
* Were confirmed to have atopic dermatitis (AD) at least 12 months ago.
* Are not having an effective treatment result from medicines that are applied on skin for AD.
* Are considered by their doctors to have moderate to severe AD.

Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20.

Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

Marietta, GA

Panama City, FL

Scottsdale, AZ

Northridge, CA

Bakersfield, CA

Pfizer

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.

The study is seeking participants who:

* Are aged 12 years or older.
* Were confirmed to have atopic dermatitis (AD) at least 12 months ago.
* Are not having an effective treatment result from medicines that are applied on skin for AD.
* Are considered by their doctors to have moderate to severe AD.

The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48.

Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Indianapolis, IN

Arlington, VA

Camp Hill, PA

Troy, MI

Sugar Land

Boise, ID

Huntington Beach, CA

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

West Palm Beach, FL

Miami, FL

Bay City, MI

Houston, TX

San Antonio, TX

Johnston, RI

JBR Clinical Research

Upland, CA

Spokane, WA

Sacramento, CA

Q32 Bio

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Charlotte, NC

Winter Park, FL

NMC Research

Plainfield, IN

Wendy Daigle, Director of Clinical Operations

Southshore, Metairie, LA

Norfolk Office

Boca Raton, FL

Margate, FL

Elias Dermatology - Fort Lauderdale, FL

North Miami Beach, FL

Northville, MI

Auburn Hills, MI

Woodbury, NY

Saskatoon, Canada

Calgary, Canada

Vida Dermatology South

Sparks Location

Reno - Moana Lane Location

Rocklin, CA

Women´s Health Institute

Prague, Czech Republic

Grodzisk Mazowiecki, Poland

Dupnitsa, Bulgaria

Bluefin Biomedicine, Inc.

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

West Lafayette, Indiana

Aclaris Therapeutics

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Fort Smith, AR

Derm Center

Texas Medical Center

Saint Joseph, MO

Arlington, TX

Santa Ana, CA

Novartis

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis.

The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Tampa, FL

Pharmacology Translational Unit

Miami Lakes, FL

Cypress, TX

Oakvile, Canada

Las Vegas, NV

Fountain Valley, CA

Los Angeles, CA

Santa Monica, CA

Clinical Research Institute of Southern Oregon (CRISOR)

Nektar Therapeutics

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Find clinical trials for Eczema in Atlanta, GA

Related conditions:

Eczema trials near Atlanta, GA, USA:

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Atlanta, GA

Related conditions:

Eczema trials near Atlanta, GA, USA:

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Find clinical trials for Eczema in Atlanta, GA